IP Library › Granted Patent US 12,534,517
Granted Patent B2
US 12,534,517 · App. 16/765,509 · Granted Jan 27, 2026

Highly specific zika neutralizing human antibodies

Inventors: Sean Diehl (Shelburne, VT); Aravinda de Silva (Chapel Hill, NC); Matthew Collins (Chapel Hill, NC); Ben McElvany (Burlington, VT); Huy Tu (Burlington, VT)
Assignees: The University of Vermont and State Agricultural College; The University of North Carolina at Chapel Hill
C07K16/1081A61K39/12A61K39/395A61K39/42A61P31/14C07K14/1825A61K2039/505C07K2317/33C07K2317/56C07K2317/565C07K2317/622C07K2317/76C07K2317/92C12N2770/24134
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,534,517
App. No.
16/765,509
Granted
Jan 27, 2026
Kind
B2
Abstract

Provided herein, in some embodiments, are compositions of Zika-specific antibodies and antigen-binding fragments thereof and methods of using the antibodies and antigen-binding fragments.

Claims (13)

1 . A method of treating a subject with Zika virus, comprising administering an effective amount of a composition to the subject, wherein the composition comprises:

(a) an antibody or an antigen-binding antibody fragment that binds Domain I of Zika virus (ZIKV) Envelope protein (EDI), binds ZIKV strain MR766, or binds ZIKV Envelope protein III (EDIII), wherein the antibody or antigen-binding antibody fragment comprises a heavy chain variable region and a light chain variable region, and wherein:

(i) the heavy chain variable region comprises an amino acid sequence that is identical to SEQ ID NO: 1 and the light chain variable region comprises an amino acid sequence that is identical to SEQ ID NO: 2; or

(ii) the heavy chain variable region comprises an amino acid sequence that is identical to SEQ ID NO: 3 and the light chain variable region comprises an amino acid sequence that is identical to SEQ ID NO: 4; and

(b) a pharmaceutically acceptable carrier.

2 . The method of claim 1 , wherein the antigen-binding antibody fragment is an scFv.

3 . The method of claim 1 , wherein the antibody is a full-length antibody.

4 . The method of claim 3 , wherein the full-length antibody is an IgG molecule.

5 . The method of claim 1 , wherein the antibody or the antigen-binding antibody fragment does not neutralize Dengue viruses 1-4.

6 . The method of claim 1 , wherein the antibody or the antigen-binding antibody fragment is encoded by a nucleic acid.

7 . The method of claim 1 , wherein the antibody is a human antibody.

8 . The method of claim 1 , wherein the composition is administered intramuscularly, subcutaneously, or intravenously.

9 . The method of claim 1 , wherein the subject is a human subject.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2020
From: DIEHL, SEAN; MCELVANY, BEN; TU, HUY
To: THE UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE
Reel/Frame 052711/0559 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2020
From: DE SILVA, ARAVINDA; COLLINS, MATTHEW
To: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
Reel/Frame 052711/0585 →
Continuity (2)
Provisional Application 62589006 · Nov 21, 2017
Related Publication 20210054055A1 · Feb 25, 2021
References Cited (49)
US 9334331B2 · Igawa · 2016 [cited by examiner]
US 10421807B2 · Gonzales · 2019 [cited by examiner]
US 20150328303A1 · De Silva et al. · 2015 [cited by applicant]
US 20170014502A1 · Sumathy et al. · 2017 [cited by applicant]
US 20170233459A1 · Hooper et al. · 2017 [cited by applicant]
US 20170298119A1 · Wollacott et al. · 2017 [cited by applicant]
WO WO2017132210A1 · 2017 [cited by applicant]
Al Qaraghuli et al. (2020, Nature Scientific Reports 10:13969). [cited by examiner]
Edwards et al. (2003, JMB 334:103-118). [cited by examiner]
Lloyd et al. (2009, Protein Engineering, Eng. Design & Selection 22(3): 159-168). [cited by examiner]
Goel et al. (2004, J. Immunol. 173: 7358-7367). [cited by examiner]
Khan et al. (2014, J. Immunol. 192: 5398-5405). [cited by examiner]
Poosarla et al. (2017, Biotechn. Bioeng. 114(6): 1331 -1342). [cited by examiner]
Rabia, et al. (2018, Biochemical Engineering Journal 137:365-374). [cited by examiner]
Chiu, M., et al., “Antibody structure and function: The basis for engineering therapeutics.” Antibodies 2019 8(4), 55 (Year: 2019). [cited by examiner]
Bhattacharya et al. Impact of genetic variation on three dimensional structure and function of proteins. PLoS One 12(3): e0171355, 2017. [cited by examiner]
Bork, P. Powers and pitfalls in sequence analysis: the 70% hurdle. Genome Res 10: 398-400, 2000. [cited by examiner]
Bork, P. Go hunting in sequence databases but watch out for the traps. Trends in Genetics 12(10): 425-427, 1996. [cited by examiner]
Brenner. S.E. Errors in genome annotation. Trends in Genetics 15:132-133, 1999. [cited by examiner]
Brorson et al. Mutational analysis of avidity and fine specificity of anti-levan antibodies. J Immunol 163: 6694-6701, 1999. [cited by examiner]
Brummell et al. Probing the combining site of an anti-carbohydrate antibody by saturation-mutagenesis: role of the heavy-chain CDR3 residues. Biochem 32(4): 1180-1187, 1993. [cited by examiner]
Burks et al. In vitro scanning saturation mutagenesis of an antibody binding pocket. Proc Natl Acad Sci USA 94: 412-417, 1997. [cited by examiner]
Colman Research in Immunol. 145:33-36, 1994. [cited by examiner]
Chuh et al. Chemical Methods for Encoding and Decoding of Posttranslational Modifications. Cell Chem Biol 23: 86-107, 2016. [cited by examiner]
Doerks et al. Protein annotation: detective work for function prediction. Trends in Genetics 14:248-250, 1998. [cited by examiner]
Fenton et al. Rheostat positions: a new classification of protein positions relevant to pharmacogenomics. Medicinal Chem Res 29: 1133-1146, 2020. [cited by examiner]
Gentilucci et al. Chemical Modifications Designed to Improve Peptide Stability: Incorporation of Non-Natural Amino Acids, Pseudo-Peptide Bonds, and Cyclization. Curr Pharm Design 16: 3185-3203, 2010. [cited by examiner]
Guo et al. Protein tolerance to random amino acid change. Proc Natl Acad Sci USA 101(25): 9205-9210, 2004. [cited by examiner]
Ikeuchi et al. Delicate balance among thermal stability, binding affinity, and conformational space explored by single-domain VHH antibodies. Sci Reports 11: 20624, 2021 (9 total pages). [cited by examiner]
Jang et al. The structural basis for DNA binding by an anti-DNA autobody. Mol Immunol 35: 1207-1217, 1998. [cited by examiner]
Kobayashi et al. Tryptophan H33 plays an important role in pyrimidine (6-4) pyrimidone photoproduct binding by a high-affinity antibody. Protein Engineering 12(10): 879-884, 1999. [cited by examiner]
Rudikoff et al. Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci USA 79: 1979-1983, 1982. [cited by examiner]
Skolnick et al. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends Biotechnol 18(I):34-39 2000. [cited by examiner]
Smith et al. The challenges of genome sequence annotation or “the devil is in the details”. Nature Biotechnol 15: 1222-1223, 1997. [cited by examiner]
Tokuriki et al. Stability effects of mutations and protein evolvability. Curr Opin Structural Biol 19: 596-604, 2009. [cited by examiner]
Vasudevan et al. A single amino acid change in the binding pocket alters specificity of an anti-integrin antibody AP7.4 as revealed by its crystal structure. Blood Cells Mol Diseases 32: 176-181, 2004. [cited by examiner]
Zhang et al. Comprehensize optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle. mAbs 7(1): 42-52, 2015. [cited by examiner]
Balmaseda et al., Antibody-based assay discriminates Zika virus infection from other flaviviruses. Proc Natl Acad Sci U S A. Aug. 1, 2017;114(31):8384-8389. doi: 10.1073/pnas.1704984114. Epub Jul. 17, 2017. [cited by applicant]
Dempsey LA. Zika-neutralizing antibodies. Nat Immunol. May 18, 2017;18(6):603. doi: 10.1038/ni.3762. [cited by applicant]
Stettler et al., Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science. Aug. 19, 2016;353(6301):823-826. doi: 10.1126/science.aaf8505. Epub Jul. 14, 2016. [cited by applicant]
Wang et al., Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. Sci Transl Med. Dec. 14, 2016;8(369):369ra179. [cited by applicant]
Wilson et al., A neutralization assay for Zika and Dengue viruses using a real-time PCR-based endpoint assessment. J Clin Microbiol. Aug. 9, 2017. pii: JCM.00673-17. doi:10.1128/JCM.00673-17. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2018/062233 mailed Feb. 11, 2019. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2018/062233 mailed Jun. 4, 2020. [cited by applicant]
Dai et al., Structures of the Zika Virus Envelope Protein and Its Complex with a Flavivirus Broadly Protective Antibody. Cell Host Microbe. May 11, 2016;19(5):696-704. doi: 10.1016/j.chom.2016.04.013. Epub May 2, 2016. [cited by applicant]
Robbiani et al., Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico. Cell. May 4, 2017;169(4):597-609.e11. doi: 10.1016/j.cell.2017.04.024. [cited by applicant]
Smith et al., The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. mBio. Nov. 19, 2013;4(6… [cited by applicant]
Wu et al., Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III. Emerg Microbes Infect. Oct. 11, 2017;6(10):e89. doi: 10.1038/emi.2017.79. [cited by applicant]
Zhao et al., Structural Basis of Zika Virus-Specific Antibody Protection. Cell. Aug. 11, 2016;166(4):1016-1027. doi: 10.1016/j.cell.2016.07.020. Epub Jul. 27, 2016. [cited by applicant]